CURE Pharma open to US CRO contract in February 2019 for PK/bioavailability study for thin film sildenafil, updates NASDAQ up-listing and partnering plans, CEO says
CURE Pharmaceuticals (OTC:CURR) welcomes CRO approaches in February 2019 for a pharmacokinetic/bioavailability study of its thin film formulation of sildenafil for erectile dysfunction, said CEO Robert Davidson. Once the Oxnard, California-based company has completed its pre-IND meeting
